Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alphamab Oncology ( (HK:9966) ) has shared an announcement.
Alphamab Oncology has convened its annual general meeting for June 12, 2026 in Suzhou, where shareholders will review the audited consolidated financial statements and directors’ and auditors’ reports for the year ended December 31, 2025. The meeting underscores routine but important governance, giving investors formal visibility into the company’s financial performance and management oversight.
Shareholders will also vote on granting the board authority to repurchase up to 10% of the company’s issued share capital and to issue additional shares or related convertible securities during a defined period. These mandates, common among Hong Kong–listed firms, would provide Alphamab Oncology with capital management flexibility for buybacks and future fundraising, potentially affecting share liquidity, capital structure, and existing shareholders’ dilution risk.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$9.60 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focused on oncology, developing and commercializing innovative cancer therapies. Listed in Hong Kong, it targets global oncology markets with a portfolio of biologic drugs and pipeline candidates aimed at addressing unmet medical needs in cancer treatment.
Average Trading Volume: 1,614,316
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.21B
For an in-depth examination of 9966 stock, go to TipRanks’ Overview page.